

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau


## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>5</sup> : <b>C12N 15/18, 1/21 // (C12N 1/21, C12R 1:19)</b>		A1	(11) International Publication Number: <b>WO 94/25592</b>
			(43) International Publication Date: 10 November 1994 (10.11.94)
(21) International Application Number: <b>PCT/KR94/00036</b>		Hanshin Apartment, Myunmock-dong, Joongryang-ku, Seoul 131-200 (KR). JEE, Young, Su [KR/KR]; 112-105, Woosung Apartment, Yangjae-dong, Seocho-ku, Seoul 137-130 (KR). YU, Young, Hyo [KR/KR]; 733-1201, Daerim Solgoe Apartment, Sanbon-dong, Kunpo, Kyunggi-do 435-040 (KR).  (74) Agent: LEE, Han, Young; 301, Yuyang Building, 823-11, Yoksam-dong, Kangnam-ku, Seoul 135-080 (KR).	
(22) International Filing Date: <b>25 April 1994 (25.04.94)</b>			
(30) Priority Data:			
1993/6978                      26 April 1993 (26.04.93)                      KR 1993/6979                      26 April 1993 (26.04.93)                      KR 1993/6980                      26 April 1993 (26.04.93)                      KR			
(71) Applicant (for all designated States except US): <b>DAEWOONG PHARMACEUTICAL CO., LTD. [KR/KR]; 223-23, Sangdaewon-dong, Joongwon-ku, Sungnam, Kyunggi-do 462-120 (KR).</b>		(81) Designated States: <b>AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</b>	
(72) Inventors; and		Published With international search report.	
(75) Inventors/Applicants (for US only): <b>LEE, Kang, Moon [KR/KR]; 438-17, Chunho-dong, Kangdong-ku, Seoul 134-020 (KR). PARK, Seung, Kook [KR/KR]; 409, Sanho Apartment, San 19-4, Sangdaewon-dong, Joongwon-ku, Sungnam, Kyunggi-do 462-130 (KR). NHO, Kyoo, Seung [KR/KR]; 25-1, Kileum-dong, Seongbook-ku, Seoul 136-110 (KR). KOH, Yeo, Wook [KR/KR]; 122-1304, Jukong Apartment, Eunhang-dong, Joongwon-ku, Sungnam, Kyunggi-do 462-150 (KR). KWON, Chang, Hyuk [KR/KR]; 26-307, Jangmi Apartment, Jamsil-dong, Songpa-ku, Seoul 138-220 (KR). CHUNG, Ju, Young [KR/KR]; 6-910,</b>			

(54) Title: A NOVEL GENE CODING HUMAN EPIDERMAL GROWTH FACTOR AND PROCESS FOR PREPARING THE SAME

## (57) Abstract

The present invention relates to a novel gene coding human epidermal growth factor ("hEGF") and a process for preparing the same employing a recombinant expression vector therefor. The hEGF gene of the invention is designed to contain codons ubiquitous in E. coli and the following restriction sites: HpaI at the 5' terminal, PstI at the 3' terminal and Bpu1102I, NsiI, MluI, Eco47III and AflII at a regular manner within its internal sequence. The present invention also provides a process for preparing REGF by employing an expression vector pTE105 for hEGF, which contains expression cassette comprising Omp A leader sequence, translation termination sequence and transcription termination sequence and hEGF gene; and, replication origin of pUC19, tetracycline-resistant marker and a par site for stabilization in E. coli. The hEGF is produced massively in E. coli transformed with the pTE105 (KCCM 10027).



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

A NOVEL GENE CODING HUMAN EPIDERMAL GROWTH FACTOR  
AND PROCESS FOR PREPARING THE SAME

5    BACKGROUND OF THE INVENTION

Field of the Invention

10       The present invention relates to a novel gene coding human epidermal growth factor and a process for preparing the same, more specifically, to a novel human epidermal growth factor gene and a process for preparing the same employing a recombinant expression vector therefor.

15    Description of the Prior Art

      It has been known that human epidermal growth factor (hereinafter referred to as 'hEGF') is a polypeptide hormone consisted of 53 amino acids and 3 disulfide bridges[see: 20 Cohen, S., J. Biol. Chem., 237:1555-1562(1962); Savage, C.R., Jr. et al., J. Biol. Chem., 248:7669-7672(1973); Savage, C.R., Jr. et al., J. Biol. Chem., 247:7612-7621 (1972)], and plays an important role on the growth control in mammalian cells, inter alia epidermal and epithelial 25 cells on molecular level[see: Sporn, M.B. et al., Nature (London), 313:745-747(1985); Sporn, M.B. et al., N. Engl. J. Med., 303:878-880(1980)] and the treatment of injury as well [see: Buckley, A. et al., Proc. Natl. Acad. Sci., USA, 82: 7340-7344(1985)]. Further, it has been reported that the 30 hEGF can be applied in the treatment of a stomach ulcer, grounded on the facts that it represses secretion of gastric acid into stomach[see: Gregory, H., J. Cell Sci. Suppl., 3: 11-17(1985)].

      Under the circumstances, studies on the mass produc- 35 tion of the hEGF has been actively carried out, since Starkey et al. had reported the biochemical property of hEGF purified from human urine[see: Starkey, R. H. et al.,

Science, 189:800(1975); Cohen, S. et al., Proc. Natl. Acad. Sci., USA, 72:1317(1975)]; and, several researchers have accomplished cloning of hEGF gene by the recombinant DNA technology in a successful manner[see: Smith, J. et al.,  
5 Nucleic Acids Res., 10:4467-4482(1982); Urdea, M. S. et al., Proc. Natl. Acad. Sci., USA, 80:7461-7465(1983); Oka, T. et al., Proc. Natl. Acad. Sci., USA, 82:7212-7216(1985)]. The prior art, however, have not provided the hEGF to the level of industrial application owing to its low activity  
10 and productivity.

Accordingly, studies on the elevation of activity and productivity in hEGF manufacture have been carried out, which are primarily concentrated on the preparation of the nucleotide sequence of hEGF gene efficient for its massive  
15 production and the expression vector whose regulatory function is strengthened.

#### SUMMARY OF THE INVENTION

20 In accordance with the present invention, the inventors synthesized a novel hEGF gene and a novel expression vector therefor which expresses hEGF in a massive manner and developed a process for preparing hEGF therefrom.

A primary object of the invention is, therefore, to  
25 provide a novel hEGF gene which is designed and chemically synthesized for the purpose of massive expression of hEGF in E. coli.

Another object of the invention is to provide a novel process for preparing hEGF from a recombinant expression  
30 vector comprising said hEGF gene and regulatory sequence.

#### BRIEF DESCRIPTION OF THE DRAWINGS

The above and the other objects and features of the  
35 present invention will become apparent from the following descriptions given in conjunction with the accompanying drawings, in which:

Figure 1 depicts sequence of designed hEGF gene of the invention;

Figure 2A depicts 10 oligonucleotides synthesized;

Figure 2B depicts assembly pattern of synthesized 10 oligonucleotides of Figure 2A;

Figure 3 depicts construction strategy of pUE118;

Figure 4 is a photograph showing agarose gel electrophoresis pattern of pUE118 carrying hEGF gene digested with restriction enzymes;

Figure 5 depicts the Omp A leader-universal translation termination-Trp A transcription termination sequence;

Figure 6 depicts construction strategy of pDT420;

Figure 7 depicts construction strategy of pDE135;

Figure 8 depicts construction strategy of pTC108;

Figure 9 depicts construction strategy of pTC226;

Figure 10 depicts construction strategy of pTE105;

Figure 11A is a photograph showing SDS-PAGE pattern of hEGF expressed in E. coli JM101 harboring pTE105;

Figure 11B is a photograph showing the Western blot analysis of hEGF expressed in E. coli JM101 harboring pTE105;

Figure 12 is a photograph showing SDS-PAGE pattern of hEGF expressed from E. coli JM101 harboring pTE105 in each purification step;

Figure 13 is a photograph showing SDS-PAGE pattern of purified hEGF from E. coli JM101 harboring pTE105;

Figure 14 is a chromatogram of purified hEGF by reverse phase HPLC; and,

Figure 15 is a photograph showing isoelectric focusing analysis of purified hEGF from E. coli JM101 harboring pTE105.

DETAILED DESCRIPTION OF THE INVENTION

The inventors synthesized a hEGF gene designed to maximize expression of the gene which satisfies the following requirements: first, hEGF expressed therefrom shall be the same as natural human EGF in light of amino acid sequence and protein structure; secondly, nucleotide sequence shall be designed in consideration of the codons ubiquitous in *E. coli*; thirdly, the portion of secondary structure of mRNA transcribed therefrom shall be minimized; fourthly, many unique restriction sites shall be positioned as far as possible.

In this connection, the hEGF gene of the invention is designed, based on the previously known hEGF sequence in the art[see: Gregory, H., *Nature*, 257:325(1975)]. First of all, the inventors synthesized 10 complementary oligonucleotides by using automatic Nucleotide Synthesizer in accordance with solid-phase phosphate triester method[see: Narang, S. A., *Synthesis and Applications of DNA and RNA*, Academic Press, 1987]; and, to obtain the full hEGF gene, shot-gun ligation method is employed.

The hEGF of the present invention contains the following restriction sites: HpaI at the 5' terminal, PstI at the 3' terminal and Bpu1102I, NsiI, MluI, Eco47III and AflIII within its internal sequence. Introduction of the hEGF gene to pUC18 which is a starting vector of the invention, produces the above 7 specific sites which exist as unique restriction sites in the recombinant vector. The fact that said unique sites are cleaved by their specific restriction enzymes and positioned at a regular interval, allows practical availability of the gene for mutagenesis induction, which assures high activity and stability of hEGF. Furtheron, the existence of HpaI restriction site at 5' terminal allows production of intact hEGF free of fusion protein from the expression vector therefor.

The hEGF gene of the invention is inserted into pUC18 digested with SmaI and PstI, and plasmid thus obtained is

named pUE118. E. coli JM109 is transformed with pUE118 according to Hanahan's method[see: DNA Cloning Vol.I: A Practical Approach, IRL Press, 1985, pp 109-135], and this transformant is deposited with Korean Culture Collection of  
5 Microorganisms(KCCM) located in Department of Food Engineering, College of Eng., Yonsei University, Sodaemun-gu, Seoul 120-749, Korea on April 9, 1993 in the name of E. coli DW/BT-2040(KCCM 10026).

On the other hand, it has been well known that  
10 regulation of protein expression corresponding to growth pattern of microorganism is very important in massive production of protein. In this connection, tac promoter [see: de Boer et al., DNA, 2:231-235(1983); Amann et al., Gene, 25:167-178(1983)] is introduced to the expression  
15 vector of the invention. Since the tac promoter has continuous two ribosome binding sites at the downstream[see: Shine and Dalgarno, Proc. Natl. Acad. Sci., USA, 71:1342 (1974)], it initiates the translation of the hEGF gene efficiently.

For the accurate and efficient expression and secretion of hEGF, the expression vector of the invention employs the following sequences: (1) Omp A leader sequence[see: von Gabain, A. et al., Proc. Natl. Acad. Sci., USA, 80:653-657 (1983)]; (2) universal translation termination sequence[see:  
25 P. Singleton and D. Sainsbury, Dictionary of Microbiology and Molecular Biology, 2nd Ed., Wiley, 383, 1987]; and, (3) trp A transcription termination sequence[see: Christie, G. E. et al., Proc. Natl. Acad. Sci., USA, 78:418(1981)]. Further, the expression vector contains par site for the  
30 stability in E. coli[see: Austin and Abeles, J. Mol. Biol., 169:373-387(1983)].

"Omp A leader-universal translation termination-trp A transcription termination sequence" is designed and synthesized to insert hEGF gene of the invention, which comprises  
35 restriction sites of BamHI at 5' terminal and XbaI at 3' terminal, and NaeI and PstI between Omp A leader and universal translation termination sequence.

On the other hand, it has been known that secretion of the expressed protein is decreased when ampicillin-resistant marker which codes  $\beta$ -lactamase, a secretory protein, is used to screen *E. coli* containing the vector comprising said  
5 marker, grounded on the fact that the two proteins, i.e., interested protein and  $\beta$ -lactamase, compete in the course of secretion[see: A. Oka, et al., *J. Mol. Biol.*, 147:217 (1981)]. Under the circumstance, tetracycline-resistant  
10 marker coding intracellular protein, which brings about high secretion of expressed protein by avoiding said competition, is employed in the invention instead of the ampicillin-resistant marker. As a result, it is clearly guaranteed that the expression vector of the invention expresses and secretes hEGF in high yield, and is stable in *E. coli*.

15 A commercially available plasmid pDR540 is digested with PvuII and then ligated with XbaI linker; and, double digestion with XbaI and BamHI is carried out. 2.4kb of DNA fragment thus obtained is ligated with "Omp A leader-universal translation termination-Trp A transcription  
20 termination sequence"; and named pDT420.

Double digestion of pDT420 with NaeI and PstI produces a cleavage between Omp A leader and universal translation termination sequence; and, pUE118 carrying hEGF gene of the invention is digested with HpaI and PstI to obtain hEGF  
25 gene. Then, the obtained hEGF gene is ligated with the pDT420 digested with NaeI and PstI, and the resultant is named pDE135.

Plasmid pUC19 known in the art is digested with DraI and EcoRI to obtain 1.2kb DNA fragment whose two ends are  
30 blunt-ended and cohesive for EcoRI, respectively; and, pBR322 is digested with AvaI and blunt-ended with Klenow's fragment, and digestion with EcoRI is followed to obtain 1.4kb DNA fragment. The above 1.4kb and 1.2kb DNA fragments are ligated with T<sub>4</sub> DNA ligase, and is named pTC108. As a  
35 result, pTC108 comprises tetracycline-resistant marker, multiple cloning site and replication origin of pUC19.

A par site is introduced for the stability of



expression vector in transformant and exact separation of plasmids after cell division. Plasmid pTC108 is digested with EcoRI and SmaI. On the other hand, pSC101 is digested with AvaI to obtain 3.3kb DNA fragment, which is blunt-ended with Klenow's fragment and then ligated with EcoRI linker and followed by digestion with EcoRI. The 3.3kb DNA fragment containing sticky end of EcoRI site is digested with HincII to obtain 0.37kb DNA fragment containing par site. This 0.37kb DNA fragment is ligated to the pTC108 digested with EcoRI and SmaI by T<sub>4</sub> DNA ligase, and the ligated plasmid is named pTC226.

Plasmid pTC226 is digested with AflIII, blunt-ended with Klenow fragment and digested with XbaI in a serial manner to obtain 2.5kb DNA fragment. On the other hand, pDE135 is digested with HindIII, blunt-ended with Klenow fragment and digested with XbaI in a serial manner to obtain 0.45kb DNA fragment. The 2.5kb and 0.45kb DNA fragments are ligated with T<sub>4</sub> DNA ligase, and the ligated plasmid is named pTE105.

E. coli JM101 is transformed with pTE105, and the transformant is deposited with Korean Culture Collection of Microorganisms(KCCM) located in Department of Food Engineering, College of Eng., Yonsei University, Sodaemun-gu, Seoul 120-749, Korea on April 9, 1993 in the name of E. coli DW/BT-2042(KCCM 10027).

Transformants E. coli DW/BT-2042 are grown in LB media and expression of hEGF therefrom is determined by 15% SDS-PAGE and Western blot analysis by employing commercially available hEGF(Amersham, ARN 5100, UK) as standard. The amount of expressed hEGF is determined by hEGF receptor binding analysis employing A431 cell line(ATCC CRL 1555). Culturing said transformant for 30hrs gave 343.5mg/L of hEGF, where most of the expressed hEGF was secreted out of cytosol.

The present inventors isolated hEGF from the culture, while reducing contamination of other cellular proteins and endotoxins, by employing a series of chromatographic

purification methods, i.e., Amberchrom CG71 chromatography, Q-Sepharose anion exchange chromatography and reverse phase C<sub>18</sub> preparative HPLC. The purity of purified hEGF is determined by analytical HPLC in accordance with modified method of Hayashi et al.'s[see: Hayashi, T. et al., Anal. Sci., 3: 445-449(1987)].

The present invention is further illustrated in the following examples, which should not be taken to limit the scope of the invention.

Example 1: Design of hEGF gene

The hEGF gene was firstly designed, based on the hEGF amino acid sequence and Grantham et al.'s study on the frequency of codon usage in E. coli[see: Grantham et al., Nucleic Acid Res., 9:243-274(1981)]. Then, sequence which does not cause formation of secondary structure of mRNA transcribed therefrom was selected, while examining whether the gene contains codons ubiquitous in E. coli and causes formation of secondary structure of mRNA or not, by employing PC-FOLD(Version 2.0) program[see: Turner, D. et al, Cold Spring Harbor Symp. Quant. Biol., 52:123(1987)]. The hEGF sequence thus designed carries the following two restriction sites to guarantee accurate insertion, isolation and manipulation of hEGF gene: HpaI at the 5' terminal; PstI at the down stream of translational termination codon. The hEGF sequence further comprises many unique restriction sites at a regular basis as followings:

HpaI-22bp-Bpu1102I-39bp-NsiI-25bp-MluI-  
35bp-Eco47III-21bp-AflIII-32bp-PstI

The hEGF sequence designed in the invention is disclosed in Fig. 1, which shows positions of restriction sites: HpaI at the 5' terminal, PstI at the 3' terminal, and Bpu1102I, NsiI, MluI, Eco47III and AflIII.

Example 2: Synthesis of oligonucleotides

The hEGF gene designed in Example 1 was chemically synthesized. First of all, 10 oligonucleotides consisted of 29mer to 41mer were synthesized in a separate manner. They are disclosed in Fig. 2A: in this connection, C1(30mer), C2(35mer), C3(29mer), C4(39mer) and C5(41mer) oligonucleotides have the same sequence as that of mRNA transcribed from the corresponding hEGF sequence; and, N1(29mer), N2(38mer), N3(29mer), N4(36mer) and N5 (38mer) oligonucleotides were complementary to the C5, C4, C3, C2 and C1 oligonucleotides, respectively[see: Fig. 2B]. Each oligonucleotide was synthesized by automatic Nucleotide Synthesizer(Pharmacia LKB Biotechnology, Uppsala, Sweden).

Example 3: Isolation and sequencing of oligonucleotides

Oligonucleotides thus synthesized were separated on the silica matrix, through treatment with TTD solution (thiophenol/triethylamine/dioxane = 1/2/2, v/v) and washing with methanol, ethanol and strong ammonia water in a serial manner. The solution containing oligonucleotide thus separated was subjected in strong ammonia water at 50°C for 12hrs to remove protecting group; and concentration under vacuum condition was followed to the volume of 0.5ml, together with removal of gas. The oligonucleotide solution thus concentrated was applied on SEP-PAK cartridge(Waters Inc., MA, USA), and elution was made with acetonitrile/triethylamine solution to obtain partially purified oligonucleotide. Then, electrophoresis on 15% denatured polyacrylamide gel(TE-boric acid (pH 8.3) with 8M urea) was carried out and location of oligonucleotide in the gel was determined by the irradiation of ultraviolet rays. The gel corresponding to oligonucleotide band was cut out, oligonucleotide was eletroeluted and salts were removed on SEP-PAK cartridge connected with injector by eluting with acetonitrile/triethylamine solution. The oligonucleotides

thus isolated were labeled with  $\gamma$ - $^{32}\text{P}$ -ATP by employing T. polynucleotide kinase(New England Biolabs., #201S, USA) and sequenced in accordance with Maxam & Gilbert's method[see: Maxam, A. M. & Gilbert, W., Proc. Natl. Acad. Sci., USA, 74:560-564 (1977)].

#### Example 4: Ligation of oligonucleotides

100pmole of each oligonucleotide prepared in Example 3, where all the oligonucleotides except for two oligonucleotides(C1 and N1) were phosphorylated at 5' terminal, were placed in Eppendorf tube with the addition of 40 $\mu$ l 0.1M Tris-HCl(pH 7.5). Then, incubation was carried out at 100°C for 3min to denature oligonucleotides, and renaturation was followed by lowering temperature slowly. To the resultant were added 10units of T. DNA ligase(New England Biolabs., #202S, USA) and ligation buffer solution, and incubated at 4°C for 12hr and at room temperature for 3hrs, respectively. Then, 7% polyacrylamide gel electrophoresis and autoradiography were followed to determine the ligated hEGF sequence of the invention.

#### Example 5: Construction of pUE118 and its transformants

pUC18 known in the art(see: Norrander, J. et al, Gene, 26:101(1985)) was digested with SmaI and PstI(New England Biolabs., #141S and #140S, MA, USA; all the restriction enzymes and linkers described hereinafter were purchased from New England Biolabs., MA, USA), and ligated with hEGF gene of the present invention. Ligation was easily performed, based on its nature of blunt 5' terminal and sticky 3' terminal in hEGF gene as designed. Recombinant vector thus obtained was named pUE118[see: Fig. 3].

Then, pUE118 were digested with HpaI, PstI, Bpu1102I, NsiI, MluI, Eco47III and AflIII, respectively, and electrophoresis of the gene fragments produced was carried out on 1% agarose gel. As disclosed in Fig. 4, the insertion of

hEGF gene was carried out in an accurate manner and it was confirmed that single restriction site exists for each restriction enzyme. In Fig. 4, Lane 1 is 1kb ladder DNA (BRL, USA); Lanes 2 and 3 are pUE118 digested with HpaI and PstI, respectively; Lane 4 is pUE118 digested doubly with HpaI and PstI; and, Lanes 5-9 are pUE118 digested with Bpu1102I, NsiI, MluI, Eco47III and AflII, respectively.

Competent *E. coli* JM109 was transformed with the pUE118; and *E. coli* JM109 thus transformed was deposited with the Korean Culture Center of Microorganisms(KCCM) in the name of *Escherichia coli*(DW/BT-2040) on April 9, 1993 as deposition No. KCCM 10026.

**Example 6: Synthesis of "Omp A leader-universal translation termination-Trp A transcription termination sequence"**

Oligonucleotide comprising Omp A leader, universal translation termination and trp A transcription termination sequence designed to have several restriction sites as disclosed in Fig. 5. The oligonucleotide comprises restriction sites of BamHI at 5' terminal and XbaI at 3' terminal, and NaeI and PstI between Omp A leader and universal translation termination sequence to assure that N-terminal amino acid sequence is exactly the same as original protein free of additional amino acid sequence.

First of all, Omp A leader-universal translation termination-Trp A transcription termination sequence was synthesized as following 8 oligonucleotides of 31mer or 32mer in a separate manner:

5' GATCCAAAATTATGAAAAAGACAGCTATCGGC 3'

5' GATTGCAGTGGCACTGGCTGGTTTCGCTACC 3'

5' GTAGCGCAGGCCGGCCTGCAGCTTAATTAATT 3'

5' AAGCAGCCCGCCTAATGAGCGGGCTTTTTTTT 3'

5' CTAGAAAAAAAGCCCGCTCATTAGCGGGCT 3'

5' GCTTAATTAATTAAGCTGCAGGCCGGCCTGCG 3'  
5' CTACGGTAGCGAAACCAGCCAGTGCCACTGC 3'  
5' AATCGCGATAGCTGTCTTTTTCATAATTTTG 3'

- 5 The oligonucleotides were synthesized with automatic Nucleotide Synthesizer(Pharmacia LKB Biotechnology, Uppsala, Sweden) in accordance with solid-phase phosphate triester method[see: Narang, S. A., Synthesis and Applications of DNA and RNA, Academic Press, 1987].
- 10 In an analogy to Example 3, the synthesized oligonucleotides were separated from the silica matrix; removal of protecting group and concentration were followed; isolation of oligonucleotides, labeling with  $\gamma$ -<sup>32</sup>P-ATP, denaturation and renaturation, and ligation of oligo-
- 15 nucleotides were performed.

Example 7: Construction of plasmid pDT420

- Plasmid pDR540(Pharmacia LKB Biotechnology, #27-4928-01, Upssala, Sweden) was digested with PvuII(#1032), ligated with XbaI linker and digested with XbaI(#145S) and BamHI(#136S) to obtain 2.4kb DNA fragment. Said fragment was isolated from the gel after electrophoresis of digested fragments by employing Geneclean II DNA elution kit(BIO 101 Inc., CA, USA), and ligated with "Omp A leader-universal translation termination-Trp A transcription termination sequence" prepared in Example 6 by T. DNA ligase(#202S). E. coli JM101 was transformed with the ligated DNA according to Hanahan's method[see: DNA Cloning Vol.I; A Practical Approach, IRL Press, 109-135(1985)]. From the transfor-
- 20
- 25
- 30
- 35
- mants, recombinant plasmid was isolated and sequenced in accordance with Maxam and Gilbert's method to screen recombinant plasmid containing "OmpA leader-universal translation termination-Trp A transcription termination sequence". The recombinant plasmid thus selected was named pDT420[see: Fig. 6].

**Example 8: Construction of expression vector pDE135 and determination of hEGF expression**

Double digestion on plasmid pDT420 was made with NaeI  
5 (#190S) and PstI(# 140S) to cleave the sequence between Omp  
A leader and universal translation termination sequence. On  
the other hand, plasmid pUE118 prepared in Example 5 was  
digested with HpaI(#105S) and PstI to obtain 0.17kb hEGF  
gene. hEGF gene thus obtained was ligated with pDT420  
10 cleaved with NaeI and PstI, and the ligated DNA was  
transformed into E. coli JM101. From the transformants,  
recombinant plasmid was isolated by alkaline lysis  
method[Sambrook et al., Molecular Cloning, a laboratory  
manual, 2nd Ed., Cold Spring Harbor, 1989]. Referring to  
15 PstI and HindIII restriction enzyme map, recombinant plasmid  
containing hEGF gene between Omp A leader and universal  
translation termination sequence was selected and named  
pDE135[see: Fig. 7].

E. coli JM101 was transformed with pDE135, and the  
20 transformant was cultured in LB media(Luria-Bertani;  
Molecular Cloning/a laboratory manual, 2nd Ed., CSH, 1989).  
Then, expression of hEGF was investigated by SDS-PAGE and  
Western blot analysis. Expression of hEGF was determined by  
receptor binding assay(see: M. W. Rieman, Peptides, 8:877-  
25 885(1987)) employing A431 cell line(ATCC CRL 1555) and  
commercially available hEGF(Amersham, ARN 5100, UK) as a  
standard. hEGF was expressed with a yield of 10mg/L after  
30hrs cultivation. Under the circumstance, the inventors  
assumed that the grounds of low efficiency of expression  
30 were: the biased transcriptional direction between ampi-  
cillin resistant marker and hEGF gene; competition of  
protein production; and, instability of the expression  
vector in transformant. Accordingly, the inventors  
determined to develop an improved hEGF expression cassette  
35 to solve the above confronted problems by employing  
tetracycline resistant marker whose product was not secreted  
out of cytosol, instead of ampicillin resistant marker.

Example 9: Construction of plasmid pTC108

Plasmid pBR322(Bolivar, F. et al., Gene, 2:95-113 (1977)) was digested with *Ava*I(#152S), and manipulated with  
5 Klenow's fragment(#210S) to have blunt-end. Then, the resultant was digested with *Eco*RI and followed by electrophoresis on 0.8% agarose gel, and the 1.4kb DNA fragment was obtained from gel by employing Geneclean II DNA elution kit. On the other hand, pUC19(Yanish-Perron, C., et al., Gene,  
10 33:103-119(1985)) was digested with *Dra*I(#129S) and *Eco*RI to give 1.2kb DNA fragment. The 1.2kb DNA fragment has replication origin of pUC19 to maintain high efficiency of replication and multiple cloning site to ease gene manipulation. 1.4kb and 1.2kb DNA fragments thus obtained were ligated  
15 with T<sub>4</sub> DNA ligase, and *E. coli* JM101 was transformed with the ligated DNA fragment in accordance with Hanahan's method. From the transformants, recombinant plasmid was isolated by alkaline lysis. Referring to *Eco*RI and *Afl*III restriction enzyme map, recombinant plasmid containing  
20 replication origin of pUC19, multiple cloning site and tetracycline resistant marker was selected and named pTC108[see: Fig. 8].

Example 10: Construction of plasmid pTC226

25

The inventors introduced *par* site for the stability of expression vector in transformant and easy separation of plasmids after cell division. Plasmid pSC101(Cohen and Chang, Proc. Natl. Acad. Sci., USA, 70:1293-1297(1973); KCTC  
30 11251) was digested with *Ava*I(#152S) and electrophoresed on 0.8% agarose gel; and, 3.3kb DNA fragment was obtained therefrom by employing Geneclean II DNA elution kit. DNA fragment thus obtained was manipulated with Klenow's fragment to produce blunt-end, ligated with *Eco*RI linker  
35 (#1020) and digested with *Eco*RI. The 3.3kb DNA fragment containing sticky end of *Eco*RI site was digested with *Hinc*II(#103S) and electrophoresed on 0.8% agarose gel.



0.37kb DNA fragment containing par site was obtained from electrophoresed gel by employing Geneclean II DNA elution kit. The obtained DNA fragment was ligated to pTC108 digested with EcoRI and SmaI(#141S) by the aid of T<sub>4</sub> DNA ligase, and E. coli JM101 was transformed with the ligated DNA fragment in accordance with Hanahan's method. From the transformants, recombinant plasmid was isolated by alkaline lysis. Referring to EcoRI and PstI restriction enzyme map, recombinant plasmid containing par site was selected and named pTC226[see: Fig 9].

Example 11: Construction of expression vector pTE105

The inventors constructed plasmid vector which is stable in E. coli and is of high efficiency of hEGF expression, by inserting hEGF gene expression cassette of the pDE135 into pTC226 to have same transcriptional direction. Plasmid pTC226 was digested with AflIII, manipulated with Klenow fragment to produce blunt-end, digested with XbaI(#145S) and electrophoresed on 0.8% agarose gel; and, 2.5kb DNA fragment was obtained from electrophoresed gel by employing Geneclean II DNA elution kit. In the same manner, plasmid pDE135 was digested with HindIII(#104S), blunt-ended with Klenow fragment, digested with XbaI and electrophoresed on 1% agarose gel; and, 0.45kb DNA fragment was obtained from electrophoresed gel by employing Geneclean II DNA elution kit. Each isolated DNA fragment, i.e., 2.5kb and 0.45kb DNA fragments, was ligated with T<sub>4</sub> DNA ligase, and E. coli JM101 was transformed with the ligated DNA fragment in accordance with Hanahan's method. From the transformant, recombinant plasmid was isolated by alkaline lysis. Referring to restriction EcoRI and BamHI enzyme map, a recombinant plasmid containing tetracycline resistant marker, par site, and Omp A leader and hEGF gene was selected and named pTE105[see: Fig. 10]. E. coli JM101 transformed with pTE105 was named DW/BT-2042, and deposited with the Korean Culture Collection of Micro-

organisms(KCCM) on April 9, 1993 as deposition No. KCCM 10027.

Example 12: Expression of hEGF in transformants

5

Transformant *E. coli* DW/BT-2042(KCCM 10027) was cultured in LB media for 5hrs with the addition of isopropyl 8-D-thio-galactoside(IPTG, Sigma I-6758) to the final concentration of 1mM; and, cultures for 19hrs and 25hrs were collected and centrifuged respectively. The supernatants were electrophoresed on 15% polyacrylamide gel(see; H. Schagger et al., Anal. Biochem., 166:368-379(1987)) employing commercially available hEGF(Amersham, ARN 5100, UK) as a standard. Fig. 11A showed that molecular size of hEGF expressed is determined as 6,000 dalton. Western blot analysis(W. N. Burnett, Anal. Biochem., 112:195-203(1981)) was also carried out to confirm that the produced was hEGF[see: Fig. 11B]. In Figs. 11A and 11B, Lane 1 is molecular weight marker(Sigma, #MW-SDS-17S); Lane 2 is the standard hEGF; Lane 3 is the culture for 24hrs without addition of IPTG; Lane 4 is the culture for 30hrs without addition of IPTG; Lane 5 is the culture for 24hrs with addition of IPTG ; and, Lane 6 is the culture for 30hrs with addition of IPTG. The amount of the hEGF in cultures for 24hrs and 30hrs were analyzed quantitatively by hEGF receptor binding assay; and disclosed in Table 1.

As clearly illustrated in Table 1, it was determined that: total hEGF amount of cultivation for 30hrs was 343.5mg/L and most of expressed hEGF was secreted out of cytosol.

30

Table 1:

Incubation time sample	24 hours	30 hours
Periplasm	10.5mg/L	9.4mg/L
Culture	213.8mg/L	334.1mg/L
Total	224.3mg/L	343.5mg/L

35

Example 13: Mass production of hEGF

Transformant E. coli DW/BT-2042(KCCM 10027) was cultured in 4ml of LB media containing 0.5% glucose and 12.5µg/ml of tetracycline at 37°C for 11hrs; and, 400µl of the culture was inoculated on 100ml of the same media and incubated for 11hrs to obtain seed culture. 80ml of seed culture was inoculated to 2L of media containing bacto-trypton 10g, yeast extract 20g, KH<sub>2</sub>PO<sub>4</sub> 3g, Na<sub>2</sub>HPO<sub>4</sub>·8H<sub>2</sub>O 4g, (NH<sub>4</sub>)<sub>2</sub>HPO<sub>4</sub> 2.5g, CaCl<sub>2</sub>·2H<sub>2</sub>O 0.01g, Sigma antifoam A 1ml, glucose 5g and tetracycline 5mg per 1L, and incubated at 30°C. After 4hrs incubation, IPTG was added to the final concentration of 1mM for induction of hEGF and further incubation was carried out for 26hrs.

Example 14: Quantitative assay of produced hEGF

The amount of expressed hEGF was determined by receptor binding assay employing A431 cell line(ATCC CRL 1555), which is modified method of Rieman's[see: Rieman, M.W., Peptides, 8:877-885(1987)] and DiAugustine's[see: DiAugustine, R. P., J. Biol. Chem., 260:2807-2811(1985)]. The A431 cells were mixed with DMEM medium containing calf serum, inoculated on Costa 24well cell culture plate to 4 x 10<sup>5</sup> cells/well and incubated under 5% CO<sub>2</sub>-atmosphere at 37°C for 6 or 7 days with the change of new medium every other day. Then, removal of medium and washing with saline phosphate buffer were followed, and cells were immobilized by treatment of 10% formaldehyde for 10min. After the removal of formaldehyde was carried out by washing with saline phosphate buffer, 250µl of receptor binding buffer consisting of 1% BSA, 0.2% sodium azide and saline phosphate buffer was added to every well. To the above, were added standard hEGF solution diluted to 0.01-20ng/20µl or hEGF solution to be determined and <sup>125</sup>I-EGF(Amersham, IM196, UK) diluted to 30,000cpm/100µl in a serial manner, and incubation with shaking at 100rpm was followed for 2hrs.

Then, each well was rinsed with receptor binding buffer and bound cells thereon were separated from the well by the incubation with 250 $\mu$ l of cell lysis solution consisting of 0.1N NaOH and 1% SDS. Radioactivity of  $^{125}$ I-EGF bound cells  
5 were determined with the aid of  $\gamma$ -scintillation counter (Packard Cobra II, USA).

Example 15: Purification of hEGF

10 2L of culture prepared in Example 13 was centrifuged (Sorvall<sup>TM</sup> RC 28S, USA) at 8,000rpm for 30min. The supernatant was loaded on Amberchrom CG71(Tosohass Corp., USA) column(2.5 x 40cm) preequilibrated with 20mM Tris buffer(pH 8.0). Washing was made with 1L of the same buffer; and step  
15 elution was carried out with 500ml of 20mM Tris buffer(pH 8.0) containing 40% acetonitrile. Flow rate was controlled at 60cm/hr in the course of loading, washing and elution. The eluted hEGF fraction was stored at 4°C.

350ml of hEGF fraction obtained as above was loaded on  
20 Q-Sepharose FF(Pharmacia, USA) column(2.5 x 40cm) preequilibrated with 20mM Tris buffer(pH 8.0) and washed with 500ml of the same buffer. Elution was made with linear gradient of 0M to 0.5M NaCl in 20mM Tris buffer(pH 8.0). In this connection, flow rate was controlled at 55cm/hr during  
25 loading, washing and elution. 316.4mg of hEGF was obtained with 80 to 85% of purity.

The hEGF fraction obtained as above was adjusted to pH 6.5 with 20% phosphate solution, and loaded on C<sub>18</sub> reverse phase column(Waters Delta Prep 4000, USA, 8 x 100mm) and  
30 followed by second C<sub>18</sub> reverse phase column(8 x 100mm). The C<sub>18</sub> reverse phase columns employed were preequilibrated with 10mM phosphate buffer(pH 6.5); and, flow rate was controlled at 4ml/min. The elution of hEGF was carried out with 10mM phosphate buffer(pH 6.5, buffer A) and 10mM phosphate buffer  
35 containing 70% acetonitrile(buffer B). 98% of purity was obtained at the retention time of 29min. Table 2 illustrates HPLC chromatographic conditions for hEGF purification.

Table 2:

Retention time(min)	Flow rate (ml/min)	Buffer ratio (A/B, %)	Gradient type
0	4	0 / 100	-
2	4	74 / 26	linear
20	4	72 / 28	linear
45	4	70 / 30	linear
70	4	66 / 44	linear
75	4	0 / 100	linear
85	4	0 / 100	linear

The homogeneity of purified hEGF in process of purification was determined by SDS-PAGE(Schagger. H. et al., Anal. Biochem., 166:368-379(1987))[see: Fig. 12]. In Fig. 12, Lane A is supernatant obtained by centrifugation of culture; Lane B is proteins isolated by Amberchrom CG71 chromatography; Lane C is proteins isolated by Q-Sepharose FF anion exchange chromatography; and, Lane D is purified hEGF by C<sub>18</sub> reverse phase HPLC.

The purification step of hEGF is summarized in Table 3.

Table 3:

Purification step	Total volume (ml)	Total hEGF (mg)	Total protein (mg)	Yield (%)	Specific activity (mg hEGF/mg protein)
Culture	2,000	582.1	5,490	100	0.106
Amberchrom CG 71	350	436.5	997	74.9	0.438
Q-Sepharose FF	300	316.4	414	54.3	0.764
C <sub>18</sub> HPLC	240	282.3	285	48.4	0.990

282.3mg of purified hEGF was obtained with the yield of 48.4%. Protein concentration was determined by Bradford method(Bradford, M., Anal. Biochem., 72:248(1976)) employing protein quantitative kit(Biorad, #500-0006, USA). The molecular weight of purified hEGF was determined as 6,000

20

dalton by 15% SDS-PAGE analysis[see: Fig. 13]. In Fig. 13, Lane A is low molecular size weight marker(Biorad, #161-0304); Lane B is purified hEGF; and, Lane C is peptide marker(Sigma, #MW-SDS-17S).

5       The purity of purified hEGF was analysed in HPLC and represented in Fig. 14. As clearly disclosed in Fig. 14, it was determined that: the purity of hEGF was over 98% and degradation of C-terminal and oxidation of methionine were not occurred.

10       Finally, isoelectric focusing analysis was carried out for pI value determination in the pH range of 4 to 6 ampholite(see: Carfin, D.E., Methods Enzymol., 183:459-475 (1990)) and its result was shown in Fig. 15. In Fig. 15, Lanes A and D are low calibration isoelectric focusing  
15       analysis marker(Pharmacia, #17-0472-01, USA); Lanes B and C are 2µg of purified hEGF; and, Lane E is 4µg of purified hEGF. As well be seen in Fig. 15, it was determined that pI of the purified hEGF is 4.55, which is the same pI value of prior art hEGF.

20

Example 16: Limulus Amebocyte Lysate test

      The purified hEGF was lyophilized and followed by Limulus Amebocyte Lysate test(Associates of Cape Code, USA).  
25       The result showed that the amount of endotoxin in hEGF was below 0.36EU per 1mg, which was extremely low. Accordingly, hEGF purification process of the invention was determined to be very efficient, while reducing contamination of other cellular protein and endotoxin.

30

35

WHAT IS CLAIMED IS:

1. A human epidermal growth factor gene comprising restriction sites of HpaI at 5' terminal and PstI at 3' terminal, and Bpu1102I, NsiI, MluI, Eco47III and AflIII, whose nucleotide sequence is represented as:

5' GTT AAC AGC GAC TCC GAA TGC CCG CTG AGC CAT GAC GGC  
3' CAA TTG TCG CTG AGG CTT ACG GGC GAC TCG GTA CTG CCG  
10 TAC TGC CTG CAC GAC GGC GTA TGC ATG TAG ATC GAA GCA  
ATG ACG GAC GTG CTG CCG CAT ACG TAC ATC TAG CTT CGT  
CTG GAC AAA TAC GCG TGC AAC TGT GTT GTT GGC TAC ATC  
15 GAC CTG TTT ATG CGC ACG TTG ACA CAA CAA CCG ATG TAG  
GGC GAG CGC TGT CAG TAC CGT GAC CTT AAG TGG TGG GAA  
CCG CTC GCG ACA GTC ATG GCA CTG GAA TTC ACC ACC CTT  
20 CTG CGC TGATAACCTGCA 3'  
GAC GCG ACTATTGG 5'

2. A recombinant vector pUE118, which comprises the nucleotide sequence of claim 1.

25

3. E. coli JM109(KCCM 10026) transformed with the recombinant vector of claim 2.

4. An expression vector pTE105 for human epidermal growth factor comprising an expression cassette consisting of Omp A leader sequence, translation termination sequence and transcription termination sequence and hEGF gene, wherein the expression cassette is under transcriptional regulation by tac promoter.

35

5. The expression vector pTE105 of claim 4, which comprises replication origin and regulation site originated

from pUC19.

6. The expression vector pTE105 of claim 4, which comprises par site for its stabilization in E. coli.

5

7. The expression vector pTE105 of claim 4, which comprises restriction sites of NaeI and PstI between Omp A leader sequence and universal translation termination sequence.

10

8. E. coli JM101(KCCM 10027) transformed with the expression vector of claim 4.

9. A process for preparing human epidermal growth factor from the culture of E. coli JM101(KCCM 10027) of claim 8.

15

10. A process for preparing human epidermal growth factor, which comprises culturing E. coli JM101(KCCM 10027) of claim 8.

20

25

30

35



1/15

Hpa I    Bpu1102 I

5' GTT AAC AGC GAC TCC GAA TGC CCG CTG AGC CAT GAC GGC TAC TGC CTG  
3' CAA TTG TCG CTG AGG CTT ACG GGC GAC TCG GTA CTG CCG ATG ACG GAC

N S D S E C P L S H D G Y C L

hEGF gene

Nsi I										Mlu I					
CAC	GAC	GGC	GTA	TGC	ATG	TAG	ATC	GAA	GCA	CTG	GAC	AAA	TAC	GCG	
GTG	CTG	CCG	CAT	ACG	TAC	ATC	TAG	CTT	CGT	GAC	CTG	TTT	ATG	CGC	
H	D	G	V	C	M	Y	I	E	A	L	D	K	Y	A	

Eco47 III

<u>TGC</u>	AAC	TGT	GTT	GTT	GGC	TAC	ATC	GGC	<u>GAG</u>	<u>CGC</u>	TGT	CAG	TAC	CGT
ACG	TTG	ACA	CAA	CAA	COG	ATG	TAG	CCG	CTC	GCG	ACA	GTC	ATG	GCA
C	N	C	V	V	G	Y	I	G	E	R	C	Q	Y	R

Afl II										Pst I	
GAC	<u>CTT</u>	<u>AAG</u>	TGG	TGG	GAA	CTG	CGC	TGATAAC	<u>CTGCA</u>	3'	
CTG	GAA	TTC	ACC	ACC	CTT	GAC	GCG	ACTATTGG		5'	
D	L	K	W	W	E	L	R	(STOP)			

FIG. 1

2 /15

C1 , 30 mer : 5' GTTAACAGCGACTCCGAATGCCCGCTAGC 3'  
 C2 , 35 mer : 5' CATGACGGCTACTGCCTGCACGACGGCGTATGCAT 3'  
 C3 , 29 mer : 5' GTACATCGAAGCACTGGACAAATACGCGT 3'  
 C4 , 39 mer : 5' GCAACTGTGTTGTTGGCTACATCGGCGAGCGCTGTCAGT 3'  
 C5 , 41 mer : 5' ACCGTGACCTTAAGTGGTGGGAAGTCCGCTGATAACCTGCA 3'  
  
 N1 , 29 mer : 5' GGTATCAGCGCAGTTCACCACCTTAAG 3'  
 N2 , 38 mer : 5' GTCACGGTACTGACAGCGCTCGCGATGTAGCCAACAA 3'  
 N3 , 29 mer : 5' CACAGTTGCACGGTATTGTCCAGTGCT 3'  
 N4 , 36 mer : 5' TCGATGTACATGCATACGCCGTCGTGCAGGCAGTAG 3'  
 N5 , 38 mer : 5' CCGTCATGGCTCAGCGGCATTGGAGTCGCTGTAAAC 3'

FIG. 2A




FIG. 2B

3/15




FIG. 3

4/15




FIG. 4

5/15




FIG. 5

6/15




FIG. 6

7/15




FIG. 7

8/15




FIG. 8



9/15




FIG. 9

10/15




FIG. 10

11/15




FIG. 11A




FIG. 11B

12/15




FIG. 12

13/15




FIG. 13

14/15




FIG. 14

15/15

A B C D E




FIG. 15

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR 94/00036

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>		
IPC <sup>5</sup> : C 12 N 15/18, 1/21/(C 12 N 1/21; C 12 R 1:19)		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b>		
Minimum documentation searched (classification system followed by classification symbols)		
IPC <sup>5</sup> : C 12 N		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP, A2, 0 335 400 (HITACHI) 4 October 1989 (04.10.89), claims.	1,3,4,8-10
A	EP, A2, 0 177 915 (TAKEDA CHEMICAL INDUSTRIES) 16 April 1986 (16.04.86), claims.	1,3,4,8-10
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 22 July 1994 (22.07.94)		Date of mailing of the international search report 11 August 1994 (11.08.94)
Name and mailing address of the ISA/ AT AUSTRIAN PATENT OFFICE Kohlmarkt 8-10 A-1014 Vienna Facsimile No. 1/53424/535		Authorized officer Wolf e.h. Telephone No. 1/53424/133



**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International application No.

PCT/KR 94/00036

In Recherchenbericht angeführtes Patentdokument Patent document cited in search report Document de brevet cité dans le rapport de recherche	Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
EP A2 335400	04-10-89	DE C0 68915841	14-07-94
		EP A3 335400	20-06-90
		EP B1 335400	08-06-94
		JP A2 1247099	02-10-89
		JP A2 1247098	02-10-89
EP A2 177915	16-04-86	AT E 59861	15-01-91
		CA A1 1263619	05-12-89
		DE C0 3581255	14-02-91
		EP A3 177915	05-08-87
		EP B1 177915	09-01-91
		JP A2 62040290	21-02-87
		JP B4 6044866	15-06-94
		US A 4849350	18-07-89
		JP A2 61088881	07-05-86
		JP B4 6042833	08-06-94

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☒ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**